NasdaqGS:SIEN

Stock Analysis Report

Executive Summary

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Sientra's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

4.5%

SIEN

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

-73.0%

SIEN

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: SIEN underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: SIEN underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

SIENIndustryMarket
7 Day4.5%1.7%2.3%
30 Day-10.4%-1.7%-1.0%
90 Day5.7%-1.7%-0.7%
1 Year-73.0%-73.0%11.0%10.1%7.9%5.6%
3 Year-29.4%-29.4%70.4%65.2%45.6%36.3%
5 Yearn/a128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Sientra's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sientra undervalued compared to its fair value and its price relative to the market?

2.66x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate SIEN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate SIEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SIEN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: SIEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SIEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SIEN is good value based on its PB Ratio (2.7x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Sientra forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

28.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SIEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SIEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SIEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SIEN's revenue (24.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: SIEN's revenue (24.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if SIEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sientra performed over the past 5 years?

-38.0%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SIEN is unprofitable, and losses have increased over the past 5 years at a rate of -38% per year.

Accelerating Growth: Unable to compare SIEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SIEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: SIEN has a negative Return on Equity (-94.91%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SIEN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SIEN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sientra's financial position?


Financial Position Analysis

Short Term Liabilities: SIEN's short term assets ($203.9M) exceeds its short term liabilities ($87.6M)

Long Term Liabilities: SIEN's short term assets (203.9M) exceeds its long term liabilities (43.1M)


Debt to Equity History and Analysis

Debt Level: SIEN's debt to equity ratio (33.9%) is considered satisfactory

Reducing Debt: SIEN's debt to equity ratio has reduced from 110.4% to 33.9% over the past 5 years.


Balance Sheet

Inventory Level: SIEN has a high level of physical assets or inventory.

Debt Coverage by Assets: SIEN's debt is covered by short term assets (assets are 5.216100x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SIEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: SIEN has sufficient cash runway for 1.677624 years if free cash flow continues to reduce at historical rates of -28.5% each year.


Next Steps

Dividend

What is Sientra's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SIEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SIEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SIEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SIEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SIEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sientra's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Jeff Nugent (72yo)

3.9yrs

Tenure

US$2,997,871

Compensation

Mr. Jeffrey M. Nugent, also known as Jeff, has been the Chairman and Chief Executive Officer at Sientra, Inc. since November 12, 2015. Mr. Nugent has been a Director of Sientra, Inc. since July 2014. He se ...


CEO Compensation Analysis

Compensation vs. Market: Jeff's total compensation ($USD3.00M) is about average for companies of similar size in the US market ($USD1.82M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.2yrs

Average Tenure

55yo

Average Age

Experienced Management: SIEN's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

63yo

Average Age

Experienced Board: SIEN's board of directors are considered experienced (3.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$99,99811 Jun 19
Paul Little
EntityIndividual
Role
Chief Financial Officer
CFO, Senior VP & Treasurer
Shares17,391
Max PriceUS$5.75
BuyUS$50,00211 Jun 19
Kevin O'Boyle
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,696
Max PriceUS$5.75
BuyUS$119,99711 Jun 19
Keith Sullivan
EntityIndividual
Role
Member of the Board of Directors
Director & Advisor to MiraDry Business
Shares20,869
Max PriceUS$5.75
BuyUS$49,999,99911 Jan 19
Clarus Ventures, LLC
EntityCompany
Shares2,730,765
Max PriceUS$18.31

Ownership Breakdown


Management Team

  • Jeff Nugent (72yo)

    Chairman & CEO

    • Tenure: 3.9yrs
    • Compensation: US$3.00m
  • Charles Huiner (48yo)

    Consultant

    • Tenure: 0.08yrs
    • Compensation: US$1.29m
  • Valerie Miller (55yo)

    VP & Corporate Controller

    • Tenure: 1.6yrs
  • Keith Sullivan (61yo)

    Director & Advisor to MiraDry Business

    • Tenure: 2.2yrs
    • Compensation: US$1.40m
  • Deborah Bettencourt

    Vice President of Customer Experience & Corporate Administration

    • Tenure: 0yrs
  • Neil Bhalodkar

    Senior Director of Investor Relations and Business Analytics

    • Tenure: 1yrs
  • Jason O’Hearn

    Vice President of Sales & Professional Relations

    • Tenure: 0yrs
  • Paul Little (54yo)

    CFO, Senior VP & Treasurer

    • Tenure: 1.2yrs
    • Compensation: US$1.59m
  • Oliver Bennett

    General Counsel and VP of Compliance & Legal

    • Tenure: 1.8yrs
  • Jane Wolf

    Vice President of Marketing

    • Tenure: 0.8yrs

Board Members

  • Jeff Nugent (72yo)

    Chairman & CEO

    • Tenure: 3.9yrs
    • Compensation: US$3.00m
  • Nick Simon (65yo)

    Lead Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$197.51k
  • Kevin O'Boyle (63yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$188.76k
  • Keith Sullivan (61yo)

    Director & Advisor to MiraDry Business

    • Tenure: 2.2yrs
    • Compensation: US$1.40m
  • Philippe Schaison (57yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$296.26k
  • Mary Fisher

    Independent Director

    • Tenure: 0.8yrs

Company Information

Sientra, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sientra, Inc.
  • Ticker: SIEN
  • Exchange: NasdaqGS
  • Founded: 2003
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$306.348m
  • Shares outstanding: 49.29m
  • Website: https://sientra.com

Number of Employees


Location

  • Sientra, Inc.
  • 420 South Fairview Avenue
  • Suite 200
  • Santa Barbara
  • California
  • 93117
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SIENNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDOct 2014
S0ZDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The comp ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:30
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.